Upadacitinib Performs Well in Phase 3 Trials of Hard-to-treat Head and Neck AD
Upadacitinib (Rinvoq, AbbVie) performed well in moderate-to-severe atopic dermatitis (AD) patients with head and neck involvement, according to a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15mg or 30mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by the severity […]